

Krzysztof Selmaj

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7761890/publications.pdf>

Version: 2024-02-01

85
papers

12,625
citations

61984

43
h-index

62596

80
g-index

86
all docs

86
docs citations

86
times ranked

8952
citing authors

#	ARTICLE	IF	CITATIONS
1	A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2010, 362, 387-401.	27.0	2,314
2	Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2012, 367, 1098-1107.	27.0	1,493
3	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 209-220.	27.0	1,324
4	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 221-234.	27.0	1,322
5	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet, The</i> , 2018, 391, 1263-1273.	13.7	684
6	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 96-120.	3.0	458
7	Ofatumumab versus Teriflunomide in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2020, 383, 546-557.	27.0	358
8	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2013, 381, 2167-2175.	13.7	269
9	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology, The</i> , 2021, 20, 762-772.	10.2	261
10	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2015, 373, 1418-1428.	27.0	245
11	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology, The</i> , 2018, 17, 405-415.	10.2	238
12	Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. <i>Lancet Neurology, The</i> , 2013, 12, 756-767.	10.2	205
13	Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2013, 73, 705-713.	5.3	194
14	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology, The</i> , 2019, 18, 1009-1020.	10.2	191
15	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology, The</i> , 2019, 18, 1021-1033.	10.2	184
16	Long-term effects of fingolimod in multiple sclerosis. <i>Neurology</i> , 2015, 84, 1582-1591.	1.1	173
17	Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. <i>Neurology</i> , 2015, 84, 872-879.	1.1	137
18	Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 253-265.	3.0	126

#	ARTICLE	IF	CITATIONS
19	Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. <i>Brain</i> , 2006, 129, 1293-1305.	7.6	116
20	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2019, 18, 845-856.	10.2	110
21	Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis. <i>Archives of Neurology</i> , 2012, 69, 1259.	4.5	97
22	Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis. <i>JAMA Neurology</i> , 2016, 73, 1089.	9.0	92
23	Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS. <i>Neurology: Clinical Practice</i> , 2016, 6, 220-229.	1.6	91
24	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. <i>Lancet Neurology</i> , The, 2014, 13, 472-481.	10.2	83
25	Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005, 170, 3-10.	2.3	80
26	Sodium intake and multiple sclerosis activity and progression in <sc>BENEFIT</sc>. <i>Annals of Neurology</i> , 2017, 82, 20-29.	5.3	80
27	Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. <i>CNS Drugs</i> , 2020, 34, 185-196.	5.9	80
28	Preliminary studies of cytokine-induced functional effects on the visual pathways in the rabbit. <i>Journal of Neuroimmunology</i> , 1989, 25, 227-239.	2.3	76
29	Notch3 Inhibition in Myelin-Reactive T Cells Down-Regulates Protein Kinase C δ and Attenuates Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2008, 180, 2634-2640.	0.8	73
30	Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. <i>Journal of Neurology</i> , 2014, 261, 1794-1802.	3.6	69
31	Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 1433.	9.0	67
32	Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b. <i>Journal of Neurology</i> , 2008, 255, 480-487.	3.6	63
33	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. <i>Journal of Neurology</i> , 2013, 260, 2297-2305.	3.6	62
34	Immunoregulatory function of bone marrow mesenchymal stem cells in EAE depends on their differentiation state and secretion of PGE2. <i>Journal of Neuroimmunology</i> , 2011, 233, 106-111.	2.3	60
35	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. <i>Journal of Neurology</i> , 2016, 263, 140-149.	3.6	60
36	Stem cells ameliorate EAE via an indoleamine 2,3-dioxygenase (IDO) mechanism. <i>Journal of Neuroimmunology</i> , 2008, 193, 12-23.	2.3	58

#	ARTICLE	IF	CITATIONS
37	Notch: A new player in MS mechanisms. <i>Journal of Neuroimmunology</i> , 2010, 218, 3-11.	2.3	58
38	Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study. <i>Multiple Sclerosis Journal</i> , 2014, 20, 243-252.	3.0	51
39	Neutralising antibodies to interferon β in multiple sclerosis. <i>Journal of Neurology</i> , 2007, 254, 827-837.	3.6	48
40	Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 103-118.	3.7	48
41	Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 9, 36-46.	2.0	48
42	Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. <i>Lancet Neurology</i> , The, 2018, 17, 689-698.	10.2	48
43	Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. <i>International Journal of MS Care</i> , 2015, 17, 236-243.	1.0	47
44	MicroRNA-146a Negatively Regulates the Immunoregulatory Activity of Bone Marrow Stem Cells by Targeting Prostaglandin E2 Synthase-2. <i>Journal of Immunology</i> , 2013, 190, 5102-5109.	0.8	41
45	Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. <i>BMC Neurology</i> , 2016, 16, 117.	1.8	40
46	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 429-440.	3.0	40
47	Overcoming failure to repair demyelination in EAE: β -secretase inhibition of Notch signaling. <i>Journal of the Neurological Sciences</i> , 2008, 265, 5-11.	0.6	39
48	Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. <i>Journal of Neurology</i> , 2014, 261, 2429-2437.	3.6	37
49	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1255-1262.	3.0	37
50	Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity. <i>Journal of the Neurological Sciences</i> , 2011, 303, 50-52.	0.6	34
51	CXC Chemokine Receptors Expression during Chronic Relapsing Experimental Autoimmune Encephalomyelitis. <i>Annals of the New York Academy of Sciences</i> , 2000, 917, 135-144.	3.8	33
52	Thyroid Hormones Influence Human Dendritic Cells' Phenotype, Function, and Subsets Distribution. <i>Thyroid</i> , 2011, 21, 533-540.	4.5	32
53	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731876064.	1.0	32
54	Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 818-829.	3.0	31

#	ARTICLE	IF	CITATIONS
55	Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. <i>Multiple Sclerosis Journal</i> , 2022, 28, 132-138.	3.0	31
56	Natalizumab and the development of extensive brain lesions in neuromyelitis optica. <i>Journal of Neurology</i> , 2013, 260, 1919-1921.	3.6	23
57	Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1909-1917.	3.0	23
58	Relapse of neuromyelitis optica during pregnancy—Treatment options and literature review. <i>Clinical Neurology and Neurosurgery</i> , 2015, 130, 159-161.	1.4	19
59	Corpora amylacea from multiple sclerosis brain tissue consists of aggregated neuronal cells. <i>Acta Biochimica Polonica</i> , 2008, 55, 43-9.	0.5	19
60	Pathophysiology of the blood-brain barrier. <i>Seminars in Immunopathology</i> , 1996, 18, 57-73.	4.0	18
61	Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program. <i>Neurology and Therapy</i> , 2016, 5, 169-182.	3.2	16
62	Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, e1041.	6.0	16
63	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1424-1456.	3.0	16
64	New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland. <i>Multiple Sclerosis Journal</i> , 2017, 23, 130-142.	3.0	13
65	Novel emerging treatments for NMOSD. <i>Neurologia i Neurochirurgia Polska</i> , 2019, 53, 317-326.	1.2	11
66	Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 32-40.	2.0	9
67	Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. <i>Journal of Neurology</i> , 2020, 267, 2851-2864.	3.6	8
68	Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. <i>Current Medical Research and Opinion</i> , 2007, 23, 2823-2832.	1.9	7
69	Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102778.	2.0	7
70	SOLUBLE NOGO-A IN CSF IS NOT A USEFUL BIOMARKER FOR MULTIPLE SCLEROSIS. <i>Neurology</i> , 2009, 72, 1708-1709.	1.1	5
71	Multiple sclerosis: Presence of serum antibodies to lipids and predominance of cholesterol recognition. <i>Journal of Neuroscience Research</i> , 2017, 95, 1984-1992.	2.9	5
72	Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101865.	2.0	5

#	ARTICLE	IF	CITATIONS
73	Hyperintense Basal Ganglia on T1-Weighted Magnetic Resonance Images in a Patient With Common Variable Immunodeficiency Associated With Elevated Serum Manganese. <i>Journal of Neuroimaging</i> , 2002, 12, 84-86.	2.0	4
74	High CD6 and low chemokine receptor expression on peripheral blood lymphocytes correlates with MRI gadolinium enhancement in MS. <i>Journal of Neuroimmunology</i> , 2014, 276, 187-194.	2.3	4
75	Recommendations of the Polish Medical Society of Radiology and the Polish Society of Neurology for a protocol concerning routinely used magnetic resonance imaging in patients with multiple sclerosis. <i>Neurologia i Neurochirurgia Polska</i> , 2020, 54, 410-415.	1.2	4
76	Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1803-1805.	3.0	3
77	Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1883-1891.	3.0	2
78	Pathophysiology of the blood-brain barrier. , 1996, , 175-191.		2
79	Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110615.	1.0	2
80	MANAGEMENT OF ADVERSE REACTIONS TO ALEMTUZUMAB INFUSION. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, e4.23-e4.	1.9	1
81	ALEMTUZUMAB PERSISTENTLY SLOWS BRAIN VOLUME LOSS IN RRMS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, e1.30-e1.	1.9	0
82	DACLIZUMAB HYP IN MULTIPLE SCLEROSIS: 3-YEAR RESULTS FROM SELECTED. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, e1.48-e1.	1.9	0
83	Pactrims 2016. <i>Multiple Sclerosis Journal</i> , 2017, 23, 308-355.	3.0	0
84	Follow-on glatiramer acetate. <i>ENeurologicalSci</i> , 2018, 13, 51-52.	1.3	0
85	Recommendations of the Polish Medical Society of Radiology and the Polish Society of Neurology for a protocol concerning routinely used magnetic resonance imaging in patients with multiple sclerosis. <i>Polish Journal of Radiology</i> , 2020, 85, 272-276.	0.9	0